Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies

To date, belimumab is the only biological drug approved for the treatment of patients with active refractory SLE. We compared and critically analyzed the results of 11 observational clinical-practice-based studies, conducted in SLE referral centers. Despite the differences in endpoints and follow-up...

Descripción completa

Detalles Bibliográficos
Autores principales: Trentin, Francesca, Gatto, Mariele, Zen, Margherita, Maddalena, Larosa, Nalotto, Linda, Saccon, Francesca, Zanatta, Elisabetta, Iaccarino, Luca, Doria, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132773/
https://www.ncbi.nlm.nih.gov/pubmed/29512034
http://dx.doi.org/10.1007/s12016-018-8675-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132773/
https://www.ncbi.nlm.nih.gov/pubmed/29512034
http://dx.doi.org/10.1007/s12016-018-8675-2

Ejemplares similares